Publicacións en colaboración con investigadores/as de Universidad Autónoma de Madrid (30)

2024

  1. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

    Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096

  2. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

    Gut

2023

  1. Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency

    Haematologica, Vol. 108, Núm. 9, pp. 2551-2557

  2. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study

    The Lancet Oncology, Vol. 24, Núm. 8, pp. 913-924

  3. Modulating T Cell Responses by Targeting CD3

    Cancers, Vol. 15, Núm. 4

  4. Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV)

    Bone Marrow Transplantation

2022

  1. Predictors of use of direct oral anticoagulants in patients with venous thromboembolism: Findings from the Registro Informatizado Enfermedad Tromboembólica registry

    Frontiers in Medicine, Vol. 9

  2. The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study

    Cancers, Vol. 14, Núm. 3

  3. Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry

    Viruses, Vol. 14, Núm. 2

2021

  1. Hematopoietic cell transplantation during COVID-19 pandemic: experience from a tertiary hospital in Madrid

    Expert Review of Hematology

2020

  1. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study

    EClinicalMedicine, Vol. 25

  2. No transmission of SARS-CoV-2 in a patient undergoing allogeneic hematopoietic cell transplantation from a matched-related donor with unknown COVID-19

    Transfusion and Apheresis Science

2019

  1. Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma

    Biology of Blood and Marrow Transplantation, Vol. 25, Núm. 9, pp. 1703-1712

2018

  1. Bmi1-progenitor cell ablation impairs the angiogenic response to myocardial infarction

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 38, Núm. 9, pp. 2160-2173

  2. Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing

    Haematologica

2016

  1. Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics

    Nature Communications, Vol. 7

2015

  1. Light-chain amyloidosis presenting as a change in bleeding phenotype in a patient with mild haemophilia A

    Haemophilia

2014

  1. Evaluación del impacto de cartas de condolencia en familiares en duelo

    Medicina Paliativa, Vol. 21, Núm. 3, pp. 98-104

  2. Intravenous immunoglobulin promotes antitumor responses by modulating macrophage polarization

    Journal of Immunology, Vol. 193, Núm. 10, pp. 5181-5189

2012

  1. Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 109, Núm. 26, pp. 10534-10539